EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +5.0% ·
share flow +12.6% ·
net new positions +4.8%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | −1 |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 33.21M | +5.3% | $2.46B | 0.5% | ▲ Add | 3 | SEC ↗ ×9 |
| 2 | State Street Global Advisors ✦ (passive) | 25.81M | n/a | $1.91B | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 13.65M | +0.9% | $1.01B | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Fisher Asset Management ✦ | 9.78M | +7.7% | $723.66M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 9.42M | +372.9% | $697.22M | 0.7% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 8.25M | +14.3% | $610.90M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 5.81M | +55.7% | $430.37M | 0.5% | ▲ Add | 3 | SEC ↗ ×3 |
| 8 | T. Rowe Price ✦ | 3.30M | -6.9% | $244.13M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 9 | PRIMECAP Management ✦ | 2.04M | +14.5% | $151.28M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 1.22M | +46.6% | $90.60M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 976.82K | -0.7% | $72.31M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Baillie Gifford ✦ | 706.80K | +238.7% | $52.32M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 13 | Renaissance Technologies ✦ | 652.49K | -46.6% | $48.30M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 588.21K | New | $43.54M | 0.1% | New | 1 | SEC ↗ |
| 15 | Soros Fund Management ✦ | 250.00K | -16.7% | $18.51M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 16 | Millennium Management ✦ | 228.17K | -80.0% | $16.89M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 208.89K | +43.5% | $15.46M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 18 | Two Sigma Investments ✦ | 125.03K | +67.7% | $9.26M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 108.28K | -34.5% | $8.02M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Arrowstreet Capital ✦ | 45.99K | -48.8% | $3.40M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 16.42K | +105.8% | $1.22M | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $43.54M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 229.24K shares, $319,498 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 619 sh · $53,017
Officer · 619 sh · $54,169
Officer · 544 sh · $49,534
Officer · 2.64K sh · $237,907
Officer · 1.24K sh · $113,417
Officer · 1.15K sh · $105,893
Officer · 30.65K sh · $2.79M
Officer · 619 sh · $56,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology